Compass Pathways PLC
NASDAQ:CMPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
CN |
Compass Pathways PLC
Total Liabilities & Equity
Compass Pathways PLC
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Liabilities & Equity
$210.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Liabilities & Equity
$717.6m
|
CAGR 3-Years
20%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Liabilities & Equity
£1.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Liabilities & Equity
£921.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Liabilities & Equity
£325.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
20%
|
|
|
Niox Group PLC
LSE:NIOX
|
Total Liabilities & Equity
£76.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-17%
|
|
Compass Pathways PLC
Glance View
Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.
See Also
What is Compass Pathways PLC's Total Liabilities & Equity?
Total Liabilities & Equity
210.3m
USD
Based on the financial report for Dec 31, 2025, Compass Pathways PLC's Total Liabilities & Equity amounts to 210.3m USD.
What is Compass Pathways PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
1%
Over the last year, the Total Liabilities & Equity growth was -2%. The average annual Total Liabilities & Equity growth rates for Compass Pathways PLC have been 2% over the past three years , 1% over the past five years .
